TRP_1170x120_12-19-19

UCB

Lannett cleared to market Xyzal Oral Solution generic

Lannett cleared to market Xyzal Oral Solution generic

PHILADELPHIA — Lannett Co. has gained Food and Drug Administration approval for levocetirizine dihydrochloride oral solution, 2.5 mg/5 ml (0.5 mg/ml), an allergy medication. Lannett said its product is a generic version of Xyzal Oral Solution 2.5 mg/5 ml (0.5 mg/ml) from UCB Inc. Plans call for levocetirizine dihydrochloride oral solution to be manufactured in

PhRMA elects officers, welcomes new member UCB

PhRMA elects officers, welcomes new member UCB

WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) board of directors has elected new officers and ushered in a new member company. Joaquin Duato, worldwide chairman of pharmaceuticals at Johnson & Johnson, was elected chairman. Joseph Jimenez, chief executive officer of Novartis AG, was elected chairman-elect, and Amgen chairman and CEO Robert Bradway

Lannett to buy Kremers Urban for $1.23 billion

Lannett to buy Kremers Urban for $1.23 billion

PHILADELPHIA — Lannett Co. plans to acquire Kremers Urban Pharmaceuticals Inc., the U.S. specialty generic drug subsidiary of UCB S.A., in a $1.23 billion deal. Lannett said late Wednesday that the acquisition will add a diversified commercial product portfolio of 18 products. Kremers Urban currently markets generic products that treat a range of conditions, including